Is 10X Genomics Stock a Good Investment?
10X Genomics Investment Advice | TXG |
- Examine 10X Genomics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research 10X Genomics' leadership team and their track record. Good management can help 10X Genomics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact 10X Genomics' business and its evolving consumer preferences.
- Compare 10X Genomics' performance and market position to its competitors. Analyze how 10X Genomics is positioned in terms of product offerings, innovation, and market share.
- Check if 10X Genomics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about 10X Genomics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in 10X Genomics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if 10X Genomics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine 10X Genomics Stock
Researching 10X Genomics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.77. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. 10X Genomics has Price/Earnings To Growth (PEG) ratio of 0.13. The entity recorded a loss per share of 1.52. The firm had not issued any dividends in recent years. 10X Genomics had 1:2 split on the 17th of July 2006.
To determine if 10X Genomics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding 10X Genomics' research are outlined below:
| 10X Genomics generated a negative expected return over the last 90 days | |
| 10X Genomics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 610.78 M. Reported Net Loss for the year was (182.63 M) with profit before taxes, overhead, and interest of 414.78 M. | |
| Over 97.0% of the company shares are owned by institutional investors |
10X Genomics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in 10X Genomics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to 10X Genomics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
10X Genomics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 1.26 B.10X Genomics' profitablity analysis
The company has Net Profit Margin of (0.3) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.3) %, which entails that for every $100 of revenue, it lost $0.3.Determining 10X Genomics' profitability involves analyzing its financial statements and using various financial metrics to determine if 10X Genomics is a good buy. For example, gross profit margin measures 10X Genomics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of 10X Genomics' profitability and make more informed investment decisions.
Basic technical analysis of 10X Stock
As of the 21st of March, 10X Genomics shows the variance of 18.26, and Mean Deviation of 2.95. Compared to fundamental indicators, the technical analysis model gives you tools to check timely technical drivers of 10X Genomics, as well as the relationship between them. Please confirm 10X Genomics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if 10X Genomics is priced more or less accurately, providing market reflects its regular price of 9.95 per share. Given that 10X Genomics has information ratio of (0.12), we suggest you to validate 10X Genomics's prevailing market performance to make sure the company can sustain itself sooner or later.10X Genomics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 10X Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on 10X Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 10X Genomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
10X Genomics' Outstanding Corporate Bonds
10X Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. 10X Genomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most 10X bonds can be classified according to their maturity, which is the date when 10X Genomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| US88023UAJ07 Corp BondUS88023UAJ07 | View | |
| US88023UAH41 Corp BondUS88023UAH41 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand 10X Genomics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing 10X Genomics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 2.95 | |||
| Coefficient Of Variation | (749.21) | |||
| Standard Deviation | 4.27 | |||
| Variance | 18.26 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (0.23) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 25.31 | |||
| Value At Risk | (8.94) | |||
| Potential Upside | 6.8 | |||
| Skewness | (0.72) | |||
| Kurtosis | 2.15 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 2.95 | |||
| Coefficient Of Variation | (749.21) | |||
| Standard Deviation | 4.27 | |||
| Variance | 18.26 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (0.23) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 25.31 | |||
| Value At Risk | (8.94) | |||
| Potential Upside | 6.8 | |||
| Skewness | (0.72) | |||
| Kurtosis | 2.15 |
Consider 10X Genomics' intraday indicators
10X Genomics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of 10X Genomics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
10X Genomics time-series forecasting models is one of many 10X Genomics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary 10X Genomics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
10X Stock media impact
Far too much social signal, news, headlines, and media speculation about 10X Genomics that are available to investors today. That information is available publicly through 10X media outlets and privately through word of mouth or via 10X internal channels. However, regardless of the origin, that massive amount of 10X data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of 10X Genomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of 10X Genomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to 10X Genomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive 10X Genomics alpha.
10X Genomics Corporate Management
| James Wilbur | Chief Officer | Profile | |
| Mennah Moustafa | Chief Officer | Profile | |
| Ruth Backer | Chief Officer | Profile | |
| Florian Baumgartner | Senior Manager | Profile | |
| Jonathan Schimmel | VP Operations | Profile | |
| Jim Goodrich | Chief Operations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between 10X Genomics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.